Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus Monotherapy for Myasthenia Gravis – Dominant Benefiting Population Study
ChiCTR2200057193Phase 4Not yet recruiting
- Sponsor
- Shijiazhuang People's Hospital
- Start
- Jan 2022
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tacrolimus in myasthenia gravis (MG), sponsored by Shijiazhuang People's Hospital. Primary endpoints: Objective response rate, Disease control rate and 2 more. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
tacrolimus
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on ChiCTR2200057193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057193.